Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Oct;26(4):455–461. doi: 10.1128/aac.26.4.455

Clinical pharmacokinetics of aztreonam in cancer patients.

P G Jones, G P Bodey, E A Swabb, D H Ho, V Fainstein, J Pasternak
PMCID: PMC179944  PMID: 6542763

Abstract

The pharmacokinetics of aztreonam were studied in 25 adult patients with hematological malignancies. Two groups of nine patients each received aztreonam (1 or 2 g every 8 h) prophylactically, and seven infected patients received a therapeutic regimen of aztreonam (1.5 g every 4 h). The mean peak serum concentration after a 1-g dose of aztreonam (given over 0.5 h on day 1) was 75.5 micrograms/ml; after a 2-g dose it was 177.2 micrograms/ml. The mean peak serum concentration after a 1.5-g dose of aztreonam (given over 2 h on day 1) was 68.5 micrograms/ml. The serum half-life ranged between 1.7 and 2.0 h for all regimens studied. The urinary concentration of the metabolite of aztreonam, SQ 26,992, increased during 1 week of administration of the drug; however, serum levels of the metabolite were barely detectable.

Full text

PDF
455

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Fainstein V., Weaver S., Bodey G. P. Comparative in vitro study of SQ26,776. Antimicrob Agents Chemother. 1982 Feb;21(2):294–298. doi: 10.1128/aac.21.2.294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Pilkiewicz F. G., Remsburg B. J., Fisher S. M., Sykes R. B. High-pressure liquid chromatographic analysis of aztreonam in sera and urine. Antimicrob Agents Chemother. 1983 Jun;23(6):852–856. doi: 10.1128/aac.23.6.852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Scully B. E., Swabb E. A., Neu H. C. Pharmacology of aztreonam after intravenous infusion. Antimicrob Agents Chemother. 1983 Jul;24(1):18–22. doi: 10.1128/aac.24.1.18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Swabb E. A., Singhvi S. M., Leitz M. A., Frantz M., Sugerman A. Metabolism and pharmacokinetics of aztreonam in healthy subjects. Antimicrob Agents Chemother. 1983 Sep;24(3):394–400. doi: 10.1128/aac.24.3.394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Swabb E. A., Sugerman A. A., McKinstry D. N. Multiple-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1983 Jan;23(1):125–132. doi: 10.1128/aac.23.1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Swabb E. A., Sugerman A. A., Platt T. B., Pilkiewicz F. G., Frantz M. Single-dose pharmacokinetics of the monobactam azthreonam (SQ 26,776) in healthy subjects. Antimicrob Agents Chemother. 1982 Jun;21(6):944–949. doi: 10.1128/aac.21.6.944. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES